Pharmacosmos strengthens its cryopreservation formulations portfolio with PentaHibe® Complete

Page 1 of 1 Pharmacosmos strengthens its cryopreservation formulations portfolio with PentaHibe® Complete Holbaek, DENMARK (Sept 10th, 2024) – Pharmacosmos, a global leader in carbohydrate-based products and pharmaceuticals is proud to announce the latest addition to its innovative cryopreservation formulations portfolio: PentaHibe® Complete. This new ready-to-use cryopreservation medium, compliant with cGMP standards, represents an innovation in cell cryopreservation as it simplifies the cryopreservation process. It allows for immediate use without any preparatory steps, significantly streamlining laboratory procedures and provides the same consistent mix time after time to ensure the viability and recovery of healthy cells. Designed for cell therapies, PentaHibe® Complete demonstrates high functionality while minimizing the use of Dimethyl Sulfoxide (DMSO), known for its dose-dependent toxicity and side effects, thereby reinforcing the safety profile of the PentaHibe® portfolio. Tested across various cell types, including T cells, mesenchymal stem cells, hematopoietic stem cells, CHO cells, and HEK cells, PentaHibe® Complete offers a reliable solution for research or further manufacturing use. “The launch of PentaHibe® Complete marks a significant milestone in our ongoing effort to provide safer and more effective cryopreservation solutions," says Tobias S. Christensen, President and CEO of Pharmacosmos. "By expanding our PentaHibe® portfolio, we are not only advancing our commitment to contributing to innovation in cell therapy but also enhancing patient health through improved cryopreservation practices." PentaHibe® Complete's efficacy has been thoroughly tested, demonstrating its ability to maintain cell recovery and proliferation with lower DMSO concentrations. This advancement supports Pharmacosmos' mission to reduce adverse reactions associated with cryopreservation and offers a safer alternative for widespread use of cryopreservation media. PentaHibe® Complete is available in a ready-to-use format, supported by robust documentation to assist with regulatory submissions. This release is poised to set a new alternative in cryopreservation media, reinforcing Pharmacosmos' role as a key partner in cell therapy. For more information on PentaHibe® Complete, please visit pentahibe.com or contact our team at pentahibe@pharmacosmos.com. Contact Media: Anne-Marie Ørkild, Head of Carbohydrates Sales & Marketing Email: amo@pharmacosmos.com About Pharmacosmos Pharmacosmos Group, headquartered in Holbaek, Denmark, and founded in 1965, is a highly specialised company focused on carbohydrate chemistry and a global leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia. With companies in the UK, Nordics, Germany, the USA, and China, as well as through partners, Pharmacosmos markets its products around the world. With a strong and ongoing commitment to R&D, Pharmacosmos is able to leverage a unique carbohydrate production platform along with deep expertise in the synthesis of ironcarbohydrate complexes. The Pharmacosmos Group has more than 500 employees. Visit www.pharmacosmos.com for more information.